<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Degarelix Ferring Information</title>
    <link
      href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/css/bootstrap.min.css"
      rel="stylesheet"
    />
    <link rel="preconnect" href="https://fonts.googleapis.com" />
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
    <link
      href="https://fonts.googleapis.com/css2?family=Lato:wght@400;700&display=swap"
      rel="stylesheet"
    />

    <style>
      /* Custom Styles */
      body {
        font-family: "Lato", sans-serif;
        color: #333;
      }

      .section-container {
        padding: 60px 0;
      }

      .main-heading {
        font-weight: bold;
        color: #f08c00; /* Orange color for the main title */
        font-size: 2.2rem;
        margin-bottom: 20px;
      }

      .main-heading span {
        color: #555;
        font-weight: normal;
      }

      .sub-heading {
        max-width: 800px;
        margin-left: auto;
        margin-right: auto;
        margin-bottom: 40px;
        font-size: 1.1rem;
        color: #555;
      }

      /* Table Styles */
      .custom-table {
        border: 1px solid #dee2e6;
      }

      .custom-table thead th {
        background-color: #003366; /* Dark Blue */
        color: white;
        border-color: #dee2e6;
        vertical-align: middle;
        font-weight: normal;
      }

      .custom-table .localized-header {
        background-color: #005a9c; /* Lighter Blue */
      }

      .custom-table .high-risk-col,
      .custom-table .high-risk-header {
        background-color: #f08c00; /* Orange */
        color: white;
      }

      .custom-table td,
      .custom-table th {
        padding: 1rem;
        vertical-align: middle;
      }

      .custom-table .or-separator {
        font-weight: bold;
        color: #f08c00;
      }

      .custom-table .footer-row {
        background-color: #f08c00; /* Lighter Blue */
        color: white;
        font-weight: bold;
      }

      .citation {
        font-size: 0.8rem;
        color: #6c757d;
        margin-top: 15px;
      }

      .description-text {
        font-size: 1rem;
        color: #555;
        margin-top: 30px;
      }

      /* Button Styles */
      .btn-find-out {
        background-color: #005a9c;
        border-color: #005a9c;
        color: white;
        padding: 12px 30px;
        font-weight: bold;
        border-radius: 50px;
        margin-top: 30px;
        transition: background-color 0.3s, border-color 0.3s;
      }

      .btn-find-out:hover {
        background-color: #003366;
        border-color: #003366;
        color: white;
      }

    .no-border {
    border: none ;
}
    </style>
  </head>
  <body>
    <div class="container section-container">
      <div class="text-center">
        <h2 class="main-heading">DEGARELIX FERRING <span>licence</span></h2>
        <p class="sub-heading">
          DEGARELIX FERRING is a GnRH antagonist approved before or after
          radiotherapy for patients with
          <b
            >high-risk localised or locally advanced hormone-dependent prostate
            cancer.</b
          ><sup>12,13</sup>
        </p>
      </div>

      <div class="table-responsive">
        <table class="table table-bordered text-center custom-table">
          <thead>
            <tr>
              <th colspan="3" class="localized-header">
                Localised prostate cancer
              </th>

              <th rowspan="2">Locally advanced PCa</th>
              <th rowspan="2">Metastatic PCa</th>
            </tr>
            <tr>
              <th>Low Risk</th>
              <th>Intermediate Risk</th>
              <th class="high-risk-header">High Risk</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>PSA <10 ng/mL</td>
              <td>PSA 10-20 ng/mL</td>
              <td class="high-risk-col">PSA >20 ng/mL</td>
              <td>Any PSA</td>
              <td>Any PSA</td>
            </tr>
            <tr>
                
              <td>+ Gleason score <7</td>
              <td>
                <span class="or-separator">OR</span><br />Gleason score =7
              </td>
              <td class="high-risk-col">
                <span class="or-separator">OR</span><br />Gleason score >7
              </td>
              <td>Any Gleason score</td>
              <td>Any Gleason score</td>
            </tr>
            <tr>
              <td>cT1-2a</td>
              <td><span class="or-separator">OR</span> T2b</td>
              <td class="high-risk-col">
                <span class="or-separator">OR</span> T2c
              </td>
             <td>T3-4 or N1</td>
              <td>T3/4, N1, M1</td>
            </tr>
            <tr>
                <td class="no-border"></td>
                <td class="no-border"></td>
              <td colspan="3" class="footer-row">DEGARELIX FERRING</td>
            </tr>
          </tbody>
        </table>
      </div>

      <p class="text-center citation">
        Adapted from European Association of Urology Guidelines, 2022.
      </p>

      <p class="text-center description-text">
        DEGARELIX FERRING is indicated for the treatment of adult male patients
        with advanced hormone-dependent prostate cancer, also in combination
        with radiotherapy and as neo-adjuvant treatment prior to radiotherapy in
        patients with high-risk localised or locally hormone-dependent dependent
        prostate cancer.<sup>12,13</sup>
      </p>

      <div class="text-center">
        <a href="#" class="btn btn-find-out">Find out more</a>
      </div>
    </div>


    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/js/bootstrap.bundle.min.js"></script>
  </body>
</html>
